LSNE Contract Manufacturing and Selecta Biosciences signs manufacturing supply agreement

LSNE Contract Manufacturing announced that it has signed a manufacturing supply agreement with Selecta Biosciences to support the development of biologic therapies for rare and serious diseases that avoid the immune responses that compromise efficacy and lead to life-threatening complications, LSNE will provide drug substance manufacturing and fill/finish services.

LSNE president and CEO, Matthew Halvorsen said that they are very excited to expand their existing relationship with Selecta. Their expertise in development and GMP manufacturing makes us a strong partner for their project. They look forward to working with their team on the late stage clinical programs, as well as future commercial manufacturing.

Selecta COO, Lloyd Johnston said that Selecta is focused on ensuring that it has the right processes and partners as they advance their lead program, SEL-212, through the clinic and toward the commercial stage. They are happy to have LSNE’s support as a clinical and commercial manufacturer of SVP-Rapamycin for SEL-212 and future product candidates.